ESMO: Novartis' Pluvicto shows significant rPFS benefit

Swiss pharma giant Novartis (NOVN: VX) today presented data from the Phase III PSMAfore trial of Pluvicto (lutetium (177Lu) vipivotide tetraxetan) at the 2023 European Society for Medical Oncology (ESMO) Congress.

The Phase III PSMAfore trial with Pluvicto, a radioligand therapy (RLT) for patients with PSMA-positive metastatic castration-resistant prostate cancer (mCRPC), met its primary endpoint of radiographic progression-free survival (rPFS), with a hazard ratio of 0.41.

Furthermore, in an updated rPFS analysis (using a data cut off with a median of 8.6 months longer study follow-up), Pluvicto demonstrated a consistent and clinically-meaningful rPFS benefit, more than doubling time to radiographic disease progression compared to a change of androgen receptor pathway inhibitor (ARPI) therapy (12.0 versus 5.6 median months). Patients with metastatic prostate cancer have a five-year survival rate of 30% and those who experience disease progression face a lack of suitable treatment options that improve long-term outcomes and preserve quality of life.